Characterization of human septic sera induced gene expression modulation in human myocytes

International Journal of Clinical and Experimental Medicine

Volumn 2, Issue 2, 2009, Pages 131-148

  Hussein, Shaimaa ^a   Michael, Paul ^a   Brabant, Danielle ^a   Omri, Abdelwahab ^a   Narain, Ravin ^a   Passi, Kaipdrum ^a   Ramana, Chilakamarti V ^b   Parrillo, Joseph E ^c   Kumar, Anand ^c,d   Parissenti, Amadeo ^a   Kumar, Aseem ^a  

^a LAURENTIAN UNIVERSITY   (Canada)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c Department of Anesthesiology   (United States)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Gene expression modulation; Human myocytes; Septic sera

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 1BETA; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CASE REPORT; CELL CYCLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEVELOPMENTAL GENE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HEART CELL CULTURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MALE; METABOLISM; MODULATION; NUCLEOTIDE SEQUENCE; SEPSIS; UNINDEXED SEQUENCE;

EID: 67749124612     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE and Ognibene FP. Septic shock in humans. advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113: 227-42.
2. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471-7.
3. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM and Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. the ACCP/SCCM consensus conference committee. american college of chest Physicians/Society of critical care medicine. Chest 1992; 101: 1644-55.
4. Vincent JL. Cardiovascular alterations in septic shock. J Antimicrob Chemother 1998; 41 Suppl A: 9-15.
5. Zanotti S, Kumar A and Kumar A. Cytokine modulation in sepsis and septic shock. Expert Opin Investig Drugs 2002; 11: 1061-75.
6. Kumar A, Thota V, Dee L, Olson J, Uretz E and Parrillo JE. Tumor necrosis factor alpha an interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949-58.
7. Dhanantwari P, Nadaraj S, Kenessey A, Chowdhury D, Al-Abed Y, Miller EJ and Ojamaa K. Macrophage migration inhibitory factor induces cardiomyocyte apoptosis. Biochem Biophys Res Commun 2008; 371: 298-303.
8. Flierl MA, Rittirsch D, Huber-Lang MS, Sarma JV and Ward PA. Molecular events in the cardiomyopathy of sepsis. Mol Med 2008; 14: 327-36.
9. Buerke U, Carter JM, Schlitt A, Russ M, Schmidt H, Sibelius U, Grandel U, Grimminger F, Seeger W, Mueller-Werdan U, Werdan K and Buerke M. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 2008; 29: 497-503.
10. Hotchkiss RS and Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-22.
11. Kumar A, Kumar A, Michael P, Brabant D, Parissenti AM, Ramana CV, Xu X and Parrillo JE. Human serum from patients with septic shock activates transcription factors STAT1, IRF1, and NF-kappaB and induces apoptosis in human cardiac myocytes. J Biol Chem 2005; 280: 42619-26.
12. Crouser ED. Mitochondrial dysfunction in septic shock and multiple organ dysfunction syndrome. Mitochondrion 2004; 4: 729-41.
13. Suematsu N, Tsutsui H, Wen J, Kang D, Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N and Takeshita A. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation 2003; 107: 1418-23.
14. Tavernier B, Garrigue D, Boulle C, Vallet B and Adnet P. Myofilament calcium sensitivity is decreased in skinned cardiac fibres of endotoxin-treated rabbits. Cardiovasc Res 1998; 38: 472-9.
15. Behrends M and Peters J. The calcium sensitizer levosimendan attenuates endotoxin-evoked myocardial dysfunction in isolated guinea pig hearts. Intensive Care Med 2003; 29: 1802-7.
16. Sharshar T, Gray F, Lorin de la Grandmaison G, Hopkinson NS, Ross E, Dorandeu A, Orlikowski D, Raphael JC, Gajdos P and Annane D. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxide synthase after death from septic shock. Lancet 2003; 362: 1799-805.
17. Tessier JP, Thurner B, Jungling E, Luckhoff A and Fischer Y. Impairment of glucose metabolism in hearts from rats treated with endotoxin. Cardiovasc Res 2003; 60: 119-30.
18. Dhainaut JF, Huyghebaert MF, Monsallier JF, Lefevre G, Dall'Ava-Santucci J, Brunet F, Villemant D, Carli A and Raichvarg D. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75: 533-41.
19. Jia L, Takahashi M, Morimoto H, Takahashi S, Izawa A, Ise H, Iwasaki T, Hattori H, Wu KJ and Ikeda U. Changes in cardiac lipid metabolism during sepsis: The essential role of very low-density lipoprotein receptors. Cardiovasc Res 2006; 69: 545-55.
20. Okamoto I, Abe M, Shibata K, Shimizu N, Sakata N, Katsuragi T and Tanaka K. Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am J Respir Crit Care Med 2000; 162: 716-22.
21. Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS and Scalea TM. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007; 245: 611-21.
22. Tang BM, McLean AS, Dawes IW, Huang SJ and Lin RC. The use of gene-expression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2007; 176: 676-84.
23. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM and Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. the ACCP/SCCM consensus conference committee. american college of chest Physicians/Society of critical care medicine. Chest 1992; 101: 1644-55.
24. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA and Parissenti AM. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Breast Cancer Res Treat 2006; 96: 17-39.
25. Sprowl JA, Villeneuve DJ, Guo B, Young AJ, Hembruff SL and Parissenti AM. Changes in expression of cell wall turnover genes accompany inhibition of chromosome segregation by bovine protein kinase C alpha expression in saccharomyces cerevisiae. Cell Biol Int 2007; 31: 1160-72.
26. Villeneuve DJ and Parissenti AM. The use of DNA microarrays to investigate the pharmacogenomics of drug response in living systems. Curr Top Med Chem 2004; 4: 1329-45.
27. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V and Quackenbush J. TM4: A free, open-source system for microarray data management and analysis. BioTechniques 2003; 34: 374-8.
28. Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA. DAVID: Database for annotation, visualization, and integrated discovery. Genome Biol 2003; 4: P3.
29. Kumar A, Thota V, Dee L, Olson J, Uretz E and Parrillo JE. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949-58.
30. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C and Schuette W. A circulating myocardial depressant substance in humans with septic shock. septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-53.
31. Sun H, Charles CH, Lau LF and Tonks NK. MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 1993; 75: 487-93.
32. Chi H, Barry SP, Roth RJ, Wu JJ, Jones EA, Bennett AM and Flavell RA. Dynamic regulation of pro- and anti-inflammatory cytokines by MAPK phosphatase 1 (MKP-1) in innate immune responses. Proc Natl Acad Sci U S A 2006; 103: 2274-9.
33. Hammer M, Mages J, Dietrich H, Servatius A, Howells N, Cato AC and Lang R. Dual specificity phosphatase 1 (DUSP1) regulates a subset of LPS-induced genes and protects mice from lethal endotoxin shock. J Exp Med 2006; 203: 15-20.
34. Zhao Q, Wang X, Nelin LD, Yao Y, Matta R, Manson ME, Baliga RS, Meng X, Smith CV, Bauer JA, Chang CH and Liu Y. MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock. J Exp Med 2006; 203: 131-40.
35. Maier JV, Brema S, Tuckermann J, Herzer U, Klein M, Stassen M, Moorthy A and Cato AC. Dual specificity phosphatase 1 knockout mice show enhanced susceptibility to anaphylaxis but are sensitive to glucocorticoids. Mol Endocrinol 2007; 21: 2663-71.
36. Hayashi D, Kudoh S, Shiojima I, Zou Y, Harada K, Shimoyama M, Imai Y, Monzen K, Yamazaki T, Yazaki Y, Nagai R and Komuro I. Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1. Biochem Biophys Res Commun 2004; 322: 310-9.
37. Fuller SJ, Davies EL, Gillespie-Brown J, Sun H and Tonks NK. Mitogen-activated protein kinase phosphatase 1 inhibits the stimulation of gene expression by hypertrophic agonists in cardiac myocytes. Biochem J 1997; 323 ( Pt 2): 313-9.
38. Chaudhry HW, Dashoush NH, Tang H, Zhang L, Wang X, Wu EX and Wolgemuth DJ. Cyclin A2 mediates cardiomyocyte mitosis in the postmitotic myocardium. J Biol Chem 2004; 279: 35858-66.
39. Cheng RK, Asai T, Tang H, Dashoush NH, Kara RJ, Costa KD, Naka Y, Wu EX, Wolgemuth DJ and Chaudhry HW. Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circ Res 2007; 100: 1741-8.
40. Yoshizumi M, Lee WS, Hsieh CM, Tsai JC, Li J, Perrella MA, Patterson C, Endege WO, Schlegel R and Lee ME. Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. J Clin Invest 1995; 95: 2275-80.
41. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Suarez EE, Atluri P and Chaudhry HW. Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2. J Thorac Cardiovasc Surg 2007; 133: 927-33.
42. Sucharov CC, Dockstader K and McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell 2008.
43. Black BL and Olson EN. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu Rev Cell Dev Biol 1998; 14: 167-96.
44. Molkentin JD and Olson EN. Combinatorial control of muscle development by basic helix-loop-helix and MADS-box transcription factors. Proc Natl Acad Sci U S A 1996; 93: 9366-73.
45. Berger I, Bieniossek C, Schaffitzel C, Hassler M, Santelli E and Richmond TJ. Direct interaction of Ca2+/calmodulin inhibits histone deacetylase 5 repressor core binding to myocyte enhancer factor 2. J Biol Chem 2003; 278: 17625-35.
46. Zhu X, Bernecker OY, Manohar NS, Hajjar RJ, Hellman J, Ichinose F, Valdivia HH and Schmidt U. Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis. Crit Care Med 2005; 33: 598-604.
47. Sayeed MM. Signaling mechanisms of altered cellular responses in trauma, burn, and sepsis: Role of Ca2+. Arch Surg 2000; 135: 1432-42.
48. Grozinger CM and Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci U S A 2000; 97: 7835-40.
49. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR and Olson EN. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000; 105: 1395-406.
50. Escames G, Lopez LC, Ortiz F, Lopez A, Garcia JA, Ros E and Acuna-Castroviejo D. Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J 2007; 274: 2135-47.
51. Gouya L, Martin-Schmitt C, Robreau AM, Austerlitz F, Da Silva V, Brun P, Simonin S, Lyoumi S, Grandchamp B, Beaumont C, Puy H and Deybach JC. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 2006; 78: 2-14.
52. Spiekerkoetter U, Sun B, Khuchua Z, Bennett MJ and Strauss AW. Molecular and phenotypic heterogeneity in mitochondrial trifunctional protein deficiency due to beta-subunit mutations. Hum Mutat 2003; 21: 598-607.
53. Peters LL, Lane PW, Andersen SG, Gwynn B, Barker JE and Beutler E. Downeast anemia (dea), a new mouse model of severe nonspherocytic hemolytic anemia caused by hexokinase (HK(1)) deficiency. Blood Cells Mol Dis 2001; 27: 850-60.
54. Azoulay-Zohar H, Israelson A, Abu-Hamad S and Shoshan-Barmatz V. In self-defence: Hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death. Biochem J 2004; 377: 347-55.
55. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong RC and Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. J Clin Invest 2003; 111: 1497-504.
56. Morris EJ, Michaud WA, Ji JY, Moon NS, Rocco JW and Dyson NJ. Functional identification of Api5 as a suppressor of E2F-dependent apoptosis in vivo. PLoS Genet 2006; 2: e196.
57. Karlsson S, Pettila V, Tenhunen J, Lund V, Hovilehto S, Ruokonen E and Finnsepsis Study Group. Vascular endothelial growth factor in severe sepsis and septic shock. Anesth Analg 2008; 106: 1820-6.
58. Yang M, Wu J, Martin CM, Kvietys PR and Rui T. Important role of p38 MAP kinase/NF-kappaB signaling pathway in the sepsis-induced conversion of cardiac myocytes to a proinflammatory phenotype. Am J Physiol Heart Circ Physiol 2008; 294: H994-1001.
59. Thompson CB, Wang CY, Ho IC, Bohjanen PR, Petryniak B, June CH, Miesfeldt S, Zhang L, Nabel GJ and Karpinski B. Cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel ets-related protein, elf-1. Mol Cell Biol 1992; 12: 1043-53.
60. Galang CK, Muller WJ, Foos G, Oshima RG and Hauser CA. Changes in the expression of many ets family transcription factors and of potential target genes in normal mammary tissue and tumors. J Biol Chem 2004; 279: 11281-92.
61. Takahashi K, Hayashi N, Shimokawa T, Umehara N, Kaminogawa S and Ra C. Cooperative regulation of fc receptor gamma-chain gene expression by multiple transcription factors, including Sp1, GABP, and elf-1. J Biol Chem 2008; 283: 15134-41.
62. Chang PY and Miyamoto S. Nuclear factor-kappaB dimer exchange promotes a p21(waf1/cip1) superinduction response in human T leukemic cells. Mol Cancer Res 2006; 4: 101-12.
63. Gallant S and Gilkeson G. ETS transcription factors and regulation of immunity. Arch Immunol Ther Exp (Warsz) 2006; 54: 149-63.
64. Janjua S, Stephanou A and Latchman DS. The C-terminal activation domain of the STAT-1 transcription factor is necessary and sufficient for stress-induced apoptosis. Cell Death Differ 2002; 9: 1140-6.
65. Zhang WJ, Li BH, Yang XZ, Li PD, Yuan Q, Liu XH, Xu SB, Zhang Y, Yuan J, Gerhard GS, Masker KK, Dong C, Koltun WA and Chorney MJ. IL-4-induced Stat6 activities affect apoptosis and gene expression in breast cancer cells. Cytokine 2008; 42: 39-47.
66. Bedoya F, Sandler LL and Harton JA. Pyrin-only protein 2 modulates NF-kappaB and disrupts ASC:CLR interactions. J Immunol 2007; 178: 3837-45.
67. Dorfleutner A, Bryan NB, Talbott SJ, Funya KN, Rellick SL, Reed JC, Shi X, Rojanasakul Y, Flynn DC and Stehlik C. Cellular pyrin domain-only protein 2 is a candidate regulator of inflammasome activation. Infect Immun 2007; 75: 1484-92.
68. Belmont LD and Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996; 84: 623-31.
69. Chang CL, Hora N, Huberman N, Hinderer R, Kukuruga M and Hanash SM. Oncoprotein 18 levels and phosphorylation mediate megakaryocyte polyploidization in human erythroleukemia cells. Proteomics 2001; 1: 1415-23.
70. Singer S, Ehemann V, Brauckhoff A, Keith M, Vreden S, Schirmacher P and Breuhahn K. Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis. Hepatology 2007; 46: 759-68.
71. Wei SH, Lin F, Wang X, Gao P and Zhang HZ. Prognostic significance of stathmin expression in correlation with metastasis and clinicopathological characteristics in human ovarian carcinoma. Acta Histochem 2008; 110: 59-65.
72. Liu A, Stadelmann C, Moscarello M, Bruck W, Sobel A, Mastronardi FG and Casaccia-Bonnefil P. Expression of stathmin, a developmentally controlled cytoskeleton-regulating molecule, in demyelinating disorders. J Neurosci 2005; 25: 737-47.
73. Cheon MS, Fountoulakis M, Cairns NJ, Dierssen M, Herkner K and Lubec G. Decreased protein levels of stathmin in adult brains with down syndrome and alzheimer's disease. J Neural Transm Suppl 2001; (61): 281-8.
74. Ohkawa N, Fujitani K, Tokunaga E, Furuya S and Inokuchi K. The microtubule destabilizer stathmin mediates the development of dendritic arbors in neuronal cells. J Cell Sci 2007; 120: 1447-56.
75. Yamashita H, Nakamura K, Arai H, Furumoto H, Fujimoto M, Kashiwagi S and Morimatsu M. Electrophoretic studies on the phosphorylation of stathmin and mitogen-activated protein kinases in neuronal cell death induced by oxidized very-low-density lipoprotein with apolipoprotein E. Electrophoresis 2002; 23: 998-1004.
76. Vancompernolle K, Boonefaes T, Mann M, Fiers W and Grooten J. Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death. J Biol Chem 2000; 275: 33876-82.
77. Anger T, Klintworth N, Stumpf C, Daniel WG, Mende U and Garlichs CD. RGS protein specificity towards gq- and Gi/o-mediated ERK 1/2 and akt activation, in vitro. J Biochem Mol Biol 2007; 40: 899-910.
78. Tokudome T, Kishimoto I, Horio T, Arai Y, Schwenke DO, Hino J, Okano I, Kawano Y, Kohno M, Miyazato M, Nakao K and Kangawa K. Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart. Circulation 2008; 117: 2329-39.
79. Takahashi S, Kawarabayasi Y, Nakai T, Sakai J and Yamamoto T. Rabbit very low density lipoprotein receptor: A low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci U S A 1992; 89: 9252-6.
80. Jia L, Takahashi M, Morimoto H, Takahashi S, Izawa A, Ise H, Iwasaki T, Hattori H, Wu KJ and Ikeda U. Changes in cardiac lipid metabolism during sepsis: The essential role of very low-density lipoprotein receptors. Cardiovasc Res 2006; 69: 545-55.
81. Giraud MN, Fluck M, Zuppinger C and Suter TM. Expressional reprogramming of survival pathways in rat cardiocytes by neuregulin-1beta. J Appl Physiol 2005; 99: 313-22.
82. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW, 2nd and Liao JK. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 2007; 115: 3197-204.
83. Rossi MA, Celes MR, Prado CM and Saggioro FP. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsible for cardiac dysfunction. Shock 2007; 27: 10-8.
84. Sakaguchi S, Iizuka Y, Furusawa S, Takayanagi M and Satoh S. Preventive effects of a verapamil against tumor necrosis factor-alpha-induced shock symptoms: Approached from lipoprotein metabolic disorders. Int Immunopharmacol 2002; 2: 867-73.
85. Cvijanovich N, Shanley TP, Lin R, Allen GL, Thomas NJ, Checchia P, Anas N, Freishtat RJ, Monaco M, Odoms K, Sakthivel B, Wong HR and Genomics of Pediatric SIRS/Septic Shock Investigators. Validating the genomic signature of pediatric septic shock. Physiol Genomics 2008; 34: 127-34.
86. Wong HR, Shanley TP, Sakthivel B, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Doctor A, Kalyanaraman M, Tofil NM, Penfil S, Monaco M, Tagavilla MA, Odoms K, Dunsmore K, Barnes M, Aronow BJ and Genomics of Pediatric SIRS/Septic Shock Investigators. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007; 30: 146-55.